Medifast
Sells OPTAVIA nutrition plans through independent coaches and direct customer shipping.
Something off on this page? Send us feedback.
Profile
Offers one OPTAVIA segment of meal replacements, structured plans, and metabolic-health nutrition support, with revenue from U.S. product sales shipped directly to customers. Independent coaches drive customer support and social selling, while GLP-1 adoption and coach-network health shape demand.
Runs a single OPTAVIA segment built around Essential Fuelings, structured weight plans, OPTAVIA ACTIVE, OPTAVIA ASCEND, and GLP-1 Nutrition Support. Products ship directly to U.S. customers, while independent coaches provide habit support, community, and social selling without holding inventory.
Execution depends on keeping the coach network productive, refreshing meal-replacement and metabolic-health products, and translating physician-origin credibility into behavior-change support. The model pairs packaged nutrition with the Habits of Health system rather than operating clinics or pharmacies.
Demand is shaped by GLP-1 adoption, weight-loss programs, medications, surgery, apps, wearables, and regulatory scrutiny of coach claims. All revenue comes from U.S. product sales, and coach commissions are tied to those product sales.
Company facts
Key statistics
Year to date +16.9% · Average volume (30d) 178.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Stephens | Target | $12 | |||
| Nov 5, 2024 | DA Davidson | Upgrade | Underperform | Neutral | $17.50 | $17 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | −$0.65 | −$0.28 | +56.9% | $72.7M | $76.4M | +5.1% | +34.29% |
| May 4, 2026Q1 FY26 | −$0.55 | −$0.19 | +65.5% | $69.2M | $76.0M | +9.9% | +22.48% |
| Feb 17, 2026Q4 FY25 | −$0.76 | −$0.55 | +27.6% | $71.4M | $75.1M | +5.2% | −0.83% |
| Nov 3, 2025Q3 FY25 | −$0.01 | −$0.21 | −2,000.0% | $71.4M | $89.4M | +25.2% | +0.84% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $115.7M | $105.6M | $89.4M | $75.1M | $76.0M | $76.4M | |
| Gross profit | $84.2M | $76.6M | $62.2M | $52.1M | $51.8M | $53.4M | |
| Operating income | −$1.3M | −$1.1M | −$4.1M | −$7.8M | −$1.1M | −$4.3M | |
| Net income | −$772.0K | $2.5M | −$2.3M | −$18.1M | −$2.1M | −$3.1M | |
| Diluted EPS | −$0.07 | $0.22 | −$0.21 | −$1.65 | −$0.19 | −$0.28 | |
| Gross margin | 72.8% | 72.6% | 69.5% | 69.4% | 68.1% | 69.9% | |
| Operating margin | -1.1% | -1.0% | -4.6% | -10.4% | -1.4% | -5.7% |
Fiscal years (4-quarter sums)FY21 $1.53B · FY22 $1.60B · FY23 $1.07B · FY24 $602.5M · FY25 $385.8M
Balance sheet, Jun 30, 2026Cash & short-term investments $169.8M · Total debt $27.6M · Total assets $260.4M · Shareholders' equity $196.4M
Dividends
Raised for 7 straight years — most recently to $1.65 from $1.64 in Mar 2023.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Sep 18, 2023 | Sep 19 | Nov 7 | $1.65 | |
| Jun 26, 2023 | Jun 27 | Aug 8 | $1.65 | |
| Mar 27, 2023 | Mar 28 | May 9 | $1.65 | raised from $1.64 |
| Dec 19, 2022 | Dec 20 | Feb 7 | $1.64 | |
| Sep 19, 2022 | Sep 20 | Nov 8 | $1.64 | |
| Jun 27, 2022 | Jun 28 | Aug 8 | $1.64 | |
| Mar 28, 2022 | Mar 29 | May 9 | $1.64 | raised from $1.42 |
| Dec 20, 2021 | Dec 21 | Feb 8 | $1.42 |
Ownership
Shares outstanding 11.12M · Float 7.82M · 70.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Steamboat Capital Partners, LLC | 790.7K | 7.10% | 13D | Aug 21, 2026 |
| Renaissance Technologies LLC | 778.6K | 7.00% | 13F | Aug 13, 2026 |
| Citadel Securities GP LLC | 715.9K | 6.50% | 13G | May 15, 2026 |
| Susquehanna Portfolio Strategies, LLC | 587.2K | 5.30% | 13G | Aug 14, 2026 |
| Two Sigma Investments, LP | 481.4K | 4.33% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Parsa Kiai | director | +43,150 | $12.26 |
| Aug 24, 2026 | Parsa Kiai | director | +4,329 | $12.00 |
| Aug 20, 2026 | Parsa Kiai | director | +43,150 | $11.60 |
| Aug 19, 2026 | Parsa Kiai | director | +29,337 | $11.66 |
| May 8, 2026 | Scott Schlackman | director | +2,500 | $12.65 |
Peers
- Herbalife
Distributor-led nutrition peer with weight-management shakes
- WeightWatchers
Commercial weight-management platform with clinical support
- Eli Lilly
Zepbound-led GLP-1 substitute for structured weight loss
- Novo Nordisk (ADR)
Wegovy/Ozempic GLP-1 platform reshaping weight management
- Hims & Hers Health
Digital weight-loss platform with GLP-1 medication access
- Simply Good Foods
Atkins, Quest, and OWYN overlap with Fuelings and protein snacks
- BellRing Brands
Premier Protein and Dymatize contest protein-shake demand
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medifast | $12.18 | +0.16% | $135.4M | — | — | 0.4 | −27.6% |
| Herbalife | $12.50 | +0.52% | $1.29B | 8.0 | 4.7 | 0.2 | +5.4% |
| WeightWatchers | $16.40 | +1.17% | $162.0M | — | — | 0.2 | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Hims & Hers Health | $28.86 | +0.10% | $6.43B | — | 110.6 | 2.5 | +38.3% |
| Simply Good Foods | $10.90 | −0.27% | $966.7M | — | 6.5 | 0.7 | −6.3% |
| BellRing Brands | $10.65 | −0.33% | $1.24B | 7.5 | 8.9 | 0.5 | +4.2% |
| Median | 9.6 | 13.6 | 0.7 | +4.8% |